BioNTech beats Q3 estimates, holds to mRNA cancer strategy despite trial misses
The company reported Q3 revenue above estimates and reiterated its commitment to mRNA cancer therapies after a mixed month of data.
Read at GenomeWeb โFull coverage ยท 6 outlets
- GenomeWeb ยท lead
- Investing.comEarnings call transcript: BioNTech beats Q3 2026 estimates as stock rises premarket
- ad-hoc-news.deBioNTech's October Ledger: A Lung-Cancer Signal, a Modest Breast-Cancer Win, and a Missed mRNA Endpo
- NPRWhat the latest on mRNA vaccines means for cancer
- 24/7 Wall St.Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady
- MSNBioNTech Q3 2026 earnings call transcript